Dual Combination Therapy Targeting DR5 and EMMPRIN in Pancreatic Adenocarcinoma
نویسندگان
چکیده
منابع مشابه
Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma.
The goal of the study was to assess the efficacy of combined extracellular matrix metalloprotease inducer (EMMPRIN)- and death receptor 5 (DR5)-targeted therapy for pancreatic adenocarcinoma in orthotopic mouse models with multimodal imaging. Cytotoxicity of anti-EMMPRIN antibody and anti-DR5 antibody (TRA-8) in MIA PaCa-2 and PANC-1 cell lines was measured by ATPlite assay in vitro. The distri...
متن کاملPreclinical Development Dual Combination Therapy Targeting DR5 and EMMPRIN in Pancreatic Adenocarcinoma
The goal of the study was to assess the efficacy of combined extracellular matrix metalloprotease inducer (EMMPRIN)and death receptor 5 (DR5)-targeted therapy for pancreatic adenocarcinoma in orthotopic mouse models with multimodal imaging. Cytotoxicity of anti-EMMPRIN antibody and anti-DR5 antibody (TRA-8) in MIA PaCa-2 and PANC-1 cell lines was measured by ATPlite assay in vitro. The distribu...
متن کاملAntibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy
Developing therapeutics that induce apoptosis in cancer cells has become an increasingly attractive approach for the past 30 years. The discovery of tumor necrosis factor (TNF) superfamily members and more specifically TNF-related apoptosis-inducing ligand (TRAIL), the only cytokine of the family capable of eradicating selectively cancer cells, led to the development of numerous TRAIL derivativ...
متن کاملTargeting mTOR in Pancreatic Ductal Adenocarcinoma
Treatment options for advanced pancreatic ductal adenocarcinoma (PDAC) are limited; however, new therapies targeting specific tumor-related molecular characteristics may help certain patient cohorts. Emerging preclinical data have shown that inhibition of mammalian target of rapamycin (mTOR) in specific KRAS-dependent PDAC subtypes leads to inhibition of tumorigenesis in vitro and in vivo. Earl...
متن کاملTargeting histone deacetylases in pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is a dismal disease with a median survival below 6 months and a 5-year survival rate below 1%. Effective therapies for locally advanced or metastatic tumours are missing and curatively resected patients relapse in over 80% of the cases. Although histone deacetylases (HDACs) are involved in the control of proliferation, apoptosis, differentiation, migratio...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Molecular Cancer Therapeutics
سال: 2011
ISSN: 1535-7163,1538-8514
DOI: 10.1158/1535-7163.mct-11-0581